185 related articles for article (PubMed ID: 23856774)
1. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
Patterson S; Wyllie S; Stojanovski L; Perry MR; Simeons FR; Norval S; Osuna-Cabello M; De Rycker M; Read KD; Fairlamb AH
Antimicrob Agents Chemother; 2013 Oct; 57(10):4699-706. PubMed ID: 23856774
[TBL] [Abstract][Full Text] [Related]
2. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Franzblau SG; Wan B; Wang Y; Ma Z; Cooper CB; Denny WA
J Med Chem; 2017 May; 60(10):4212-4233. PubMed ID: 28459575
[TBL] [Abstract][Full Text] [Related]
3. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.
Patterson S; Wyllie S; Norval S; Stojanovski L; Simeons FR; Auer JL; Osuna-Cabello M; Read KD; Fairlamb AH
Elife; 2016 May; 5():. PubMed ID: 27215734
[TBL] [Abstract][Full Text] [Related]
4. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
5. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.
Wyllie S; Patterson S; Stojanovski L; Simeons FR; Norval S; Kime R; Read KD; Fairlamb AH
Sci Transl Med; 2012 Feb; 4(119):119re1. PubMed ID: 22301556
[TBL] [Abstract][Full Text] [Related]
6. Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.
Wyllie S; Patterson S; Fairlamb AH
Antimicrob Agents Chemother; 2013 Feb; 57(2):901-6. PubMed ID: 23208716
[TBL] [Abstract][Full Text] [Related]
7. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Martin D; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2016 Mar; 59(6):2530-50. PubMed ID: 26901446
[TBL] [Abstract][Full Text] [Related]
8. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
Gurumurthy M; Mukherjee T; Dowd CS; Singh R; Niyomrattanakit P; Tay JA; Nayyar A; Lee YS; Cherian J; Boshoff HI; Dick T; Barry CE; Manjunatha UH
FEBS J; 2012 Jan; 279(1):113-25. PubMed ID: 22023140
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
Somasundaram S; Anand RS; Venkatesan P; Paramasivan CN
BMC Microbiol; 2013 Oct; 13():218. PubMed ID: 24083570
[TBL] [Abstract][Full Text] [Related]
10. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
11. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
Denny WA; Palmer BD
Future Med Chem; 2010 Aug; 2(8):1295-304. PubMed ID: 21426020
[TBL] [Abstract][Full Text] [Related]
12. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
13. β-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasis.
Chandrakar P; Gunaganti N; Parmar N; Kumar A; Singh SK; Rashid M; Wahajuddin M; Mitra K; Narender T; Kar S
Eur J Med Chem; 2019 Nov; 182():111632. PubMed ID: 31499363
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity and in vivo efficacy of fexinidazole against New World Leishmania species.
de Morais-Teixeira E; Rabello A; Aguiar MMG
J Antimicrob Chemother; 2019 Aug; 74(8):2318-2325. PubMed ID: 31049550
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
Dogra M; Palmer BD; Bashiri G; Tingle MD; Shinde SS; Anderson RF; O'Toole R; Baker EN; Denny WA; Helsby NA
Br J Pharmacol; 2011 Jan; 162(1):226-36. PubMed ID: 20955364
[TBL] [Abstract][Full Text] [Related]
16. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.
Want MY; Islammudin M; Chouhan G; Ozbak HA; Hemeg HA; Chattopadhyay AP; Afrin F
Int J Nanomedicine; 2017; 12():2189-2204. PubMed ID: 28356736
[TBL] [Abstract][Full Text] [Related]
17. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
[TBL] [Abstract][Full Text] [Related]
18.
Ramalingam K; Gangwar S; Balodi DC; Anand A; Yadav S; Biswas S; Karunakaran Sasikala AK; Gupta KC; Batra S; Goyal N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0236121. PubMed ID: 35852367
[TBL] [Abstract][Full Text] [Related]
19. Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.
Koniordou M; Patterson S; Wyllie S; Seifert K
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069646
[TBL] [Abstract][Full Text] [Related]
20. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
